Evidence map›Paper›PMID 24871945›Full record

ArticleDevelopmental cell2014

APC(Cdc20) suppresses apoptosis through targeting Bim for ubiquitination and destruction.

Lixin Wan, Mingjia Tan, Jie Yang, Hiroyuki Inuzuka, Xiangpeng Dai, Tao Wu, Jia Liu, Shavali Shaik, Guoan Chen, Jing Deng and 5 more

Open access · bronzeAbstract read
In one paragraph

Article in Developmental cell, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed, 140 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Linear ubiquitination of p31Cell & bioscience · 2025
    Article
  6. Article
  7. The Tumor Suppressor TPD52-Governed Endoplasmic Reticulum Stress is Modulated by APCAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. CDC20 promotes radioresistance of prostate cancer by activating Twist1 expression.Apoptosis : an international journal on programmed cell death · 2023
    Article
  16. Article
  17. Article
  18. CDC20: a novel therapeutic target in cancer.American journal of translational research · 2023
    Review
  19. Article
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Lixin WanDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Mingjia TanDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Jie YangDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Biochemistry and Molecular Cell Biology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiaotong University School of Medicine, Chongqing Road, Shanghai 200025, China.
Hiroyuki InuzukaDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Xiangpeng DaiDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Tao WuDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Jia LiuDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA; Institute of Mitochondrial Biology and Medicine, School of Life Science and Technology, Xi'an Jiaotong University, Xi'an, Shaanxi 710049, China.
Shavali ShaikDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
Guoan ChenThoracic Surgery, University of Michigan, Ann Arbor, MI 48109, USA.
Jing DengDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Marcos MalumbresCell Division and Cancer Group, Spanish National Cancer Research Centre (CNIO), Madrid 28029, Spain.
Anthony LetaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Marc W KirschnerDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115, USA.
Yi SunDepartment of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA.
Wenyi WeiDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. Electronic address: wwei2@bidmc.harvard.edu.
University of Michigan–Ann Arbor · USBeth Israel Deaconess Medical Center · USCenter for Systems Biology · USDana-Farber Cancer Institute · USHarvard University Press · USHarvard University · USSpanish National Cancer Research Centre · ES

Funding

CELL CYCLE REGULATIONR01GM039023 · NIGMS · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI KIRSCHNER, MARC WALLACE · 1988 to 2017
$10.2M
The role of FBXW2 as a novel lung tumor suppressor that cross-talks with oncogenic beta-TrCP and SKP2R01CA156744 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MORGAN, MEREDITH A · 2011 to 2020
$3.4M
Interplay between Cdh1 and major regulatory pathways in human cancerR01GM089763 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2009 to 2018
$3.0M
SAG E3 ubiquitin ligase in regulation of transformation and carcinogenesisR01CA118762 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SUN, YI · 2006 to 2015
$2.6M
Functional analysis of beta-TRCP in cell cycle control and DNA damage responseR01GM094777 · NIGMS · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WEI, WENYI · 2012 to 2015
$1.3M
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia TreatmentR00CA183914 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI WAN, LIXIN · 2016 to 2018
$652k
New insights into the role of the Fbw7 tumor suppressor in senescence and agingK01AG041218 · NIA · BETH ISRAEL DEACONESS MEDICAL CENTER · PI INUZUKA, HIROYUKI · 2011 to 2015
$621k
A Novel Oncogenic Role for Cdc20 Implications in Adult T Cell Leukemia TreatmentK99CA183914 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI WAN, LIXIN · 2014 to 2015
$339k
NCI NIH HHS CA118762NCI NIH HHS CA156744NCI NIH HHS K99 CA183914NCI NIH HHS R00 CA183914NCI NIH HHS R01 CA118762NCI NIH HHS R01 CA156744NIA NIH HHS K01 AG041218NIGMS NIH HHS GM089763NIGMS NIH HHS GM094777NIGMS NIH HHS GM39023NIGMS NIH HHS R01 GM039023NIGMS NIH HHS R01 GM089763NIGMS NIH HHS R01 GM094777
6 · The paper itself

Abstract

Anaphase-promoting complex Cdc20 (APC(Cdc20)) plays pivotal roles in governing mitotic progression. By suppressing APC(Cdc20), antimitotic agents activate the spindle-assembly checkpoint and induce apoptosis after prolonged treatment, whereas depleting endogenous Cdc20 suppresses tumorigenesis in part by triggering mitotic arrest and subsequent apoptosis. However, the molecular mechanism(s) underlying apoptosis induced by Cdc20 abrogation remains poorly understood. Here, we report the BH3-only proapoptotic protein Bim as an APC(Cdc20) target, such that depletion of Cdc20 sensitizes cells to apoptotic stimuli. Strikingly, Cdc20 and multiple APC-core components were identified in a small interfering RNA screen that, upon knockdown, sensitizes otherwise resistant cancer cells to chemoradiation in a Bim-dependent manner. Consistently, human adult T cell leukemia cells that acquire elevated APC(Cdc20) activity via expressing the Tax viral oncoprotein exhibit reduced Bim levels and resistance to anticancer agents. These results reveal an important role for APC(Cdc20) in governing apoptosis, strengthening the rationale for developing specific Cdc20 inhibitors as effective anticancer agents.

Indexed as

ApoptosisUbiquitinationAntimitotic AgentsApoptosis Regulatory ProteinsBcl-2-Like Protein 11Cdc20 ProteinsCell Line, TumorCell Transformation, NeoplasticChemoradiotherapyGene Products, taxHCT116 CellsHeLa CellsHTLV-I InfectionsHumansHuman T-lymphotropic virus 1Leukemia-Lymphoma, Adult T-CellAntimitotic AgentsApoptosis Regulatory ProteinsBCL2L11 protein, humanBcl-2-Like Protein 11CDC20 protein, humanCdc20 ProteinsGene Products, taxMembrane ProteinsProto-Oncogene ProteinsRNA, Small Interfering

Identifiers

PMID24871945
PMCPMC4081014
OpenAlexW1986141453

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.